When primary-cells, including non-genetically modified and genetically
modified T-cells to produce a special substance, are infused into patients, these
performances would be defined as cell therapy. An excellent cell performance with its
optimal proliferation for cell therapy should maintain its functional feature and efficacy
in vivo with ethical acceptance and safe application. Because the efficacy of cell
therapy maybe will be decreased in vivo special microenvironment after infusion,
moreover, because cell therapy with these genetically modified T-cells would be faced
by a safe challenge in clinics, a functional induction/inhibition of some genes’
expressions used in T-cell growth without genetic modification has been increasingly
studied. Here, T-cell therapy based on system biology for an induction/inhibition of
special function and maintaining a special function in vivo microenvironment is called
as functional cell therapy. Nowadays, following research and development (R&D) of
T-cell proliferatively engineering techniques and system modeling by this
computational simulation performance, the novel techniques of T-cell culture based on
genomic analysis and supported by system biology will be increasingly studied for
adoptive T-cell therapy so that oncologists can safely and effectively utilize the new
strategy for personalized immunotherapy.
Keywords: CD8+cells, Gene expression signature (GES), Heterogeneous
responses, Network, Personalized immunotherapy, Quantitative pathway, Tumorinfiltrating
lymphocytes (TILs), Tumor microenvironment (TME).
